Evidence map›Paper›PMID 33109629›Full record

ArticleJournal for immunotherapy of cancer2020

Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma.

Yaya Chu, Gaurav Nayyar, Nang Kham Su, Jeremy M Rosenblum, Patrick Soon-Shiong, John Lee, Jeffrey T Safrit, Matthew Barth, Dean Lee, Mitchell S Cairo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Targeted therapies in pediatric oncology: A start.Molecular therapy. Oncology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yaya ChuDepartment of Pediatrics, New York Medical College, Valhalla, New York, USA mitchell_cairo@nymc.edu yaya_chu@nymc.edu.
Gaurav NayyarDepartment of Pediatrics, New York Medical College, Valhalla, New York, USA.
Nang Kham SuDepartment of Pediatrics, New York Medical College, Valhalla, New York, USA.
Jeremy M RosenblumDepartment of Pediatrics, New York Medical College, Valhalla, New York, USA.
Patrick Soon-ShiongImmunityBio, Inc, Culver City, California, USA.
John LeeImmunityBio, Inc, Culver City, California, USA.
Jeffrey T SafritNantKwest, Culver City, California, USA.
Matthew BarthDepartment of Pediatrics, State University of New York at Buffalo, Buffalo, New York, USA.
Dean LeeCenter for Childhood Cancer and Blood Disorders, Abigail Wexner Research Institute of Nationwide Children's Hospital, Columbus, Ohio, USA.
Mitchell S CairoDepartment of Pediatrics, New York Medical College, Valhalla, New York, USA mitchell_cairo@nymc.edu yaya_chu@nymc.edu.ORCID 0000-0002-2075-434X
New York Medical College · USImmunityBio (United States) · USNationwide Children's Hospital · USUniversity at Buffalo, State University of New York · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognosis of patients with relapsed or progressive B cell (CD20

methodsWe investigated the anti-tumor combinatorial effects of N-820 with ex vivo expanded peripheral blood natural killer (exPBNK) cells against rituximab-sensitive and rituximab-resistant CD20

resultsN-820 significantly enhanced the expression of NK activating receptors (p<0.001) and the proliferation of exPBNK cells with enhanced Ki67 expression and Stat5 phosphorylation (p<0.001). N-820 significantly enhanced the secretion of cytokines, chemokines, and growth factors including GM-CSF, RANTES, MIP-1B (p<0.001) from exPBNK cells as compared with the combination of rituximab+N-803. Importantly, N-820 significantly enhanced in vitro cytotoxicity (p<0.001) of exPBNK with enhanced granzyme B and IFN-γ release (p<0.001) against BL. Gene expression profiles in exPBNK stimulated by N-820+Raji-2R showed enhanced transcription of

conclusionsOur results provide the rationale for the development of a clinical trial of N-820 alone or in combination with endogenous or ex vivo expanded NK cells in patients with CD20

Indexed as

AnimalsBurkitt LymphomaCytokinesFemaleHumansImmunotherapyKiller Cells, NaturalMiceMice, Inbred NODPrognosisCytokinescytotoxicityimmunologicimmunotherapytranslational medical research

Identifiers

PMID33109629
PMCPMC7592258
OpenAlexW3094672749

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.